Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeLuNa: Terbium-161 PSMA in mCRPC
NCT07441837Phase 2Not yet recruiting
- Sponsor
- Ankara University
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of [161Tb]Tb-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Ankara University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
[161Tb]Tb-PSMA-I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07441837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441837.